Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-ß-D-arabinofuranosylcytosine exposure

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 927-934

  Vrana, Julie A ^a   Rao, Anjali S ^a   Wang, Zhiliang ^a   Jarvis, W David ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A23187; Apoptosis; Bryostatin 1; Differentiation; Leukemic cells

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BRYOSTATIN 1; CALCIMYCIN; CALCIUM IONOPHORE; CYTARABINE; PHORBOL ESTER; PROTEIN KINASE C ACTIVATOR;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL DEATH; CELL STRAIN HL 60; CELL STRUCTURE; CLONOGENESIS; CONTROLLED STUDY; DNA DEGRADATION; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ACETAMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIMYCIN; CALCIUM; CELL DIFFERENTIATION; CYTARABINE; DNA FRAGMENTATION; HL-60 CELLS; HUMANS; LACTONES; MACROLIDES; TETRADECANOYLPHORBOL ACETATE;

EID: 0031915113     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kerr JFR, Winterford CM and Harmon BV: Apoptosis: its signficance in cancer and cancer therapy. Cancer 73: 2013-2016, 1994.
2. Wyllie AH, Kerr JFR and Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980.
3. Kaufmann S: Induction of endonucleolytic DNA cleavage in human acute myeloid leukemia cells etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 48: 5870-5878, 1989.
4. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR and Darzynkiewicz Z: Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7: 659-670, 1993.
5. Martin SJ, Bradley JG and Cotter TG: HL-60 cells differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 79: 448-453, 1990.
6. Solary E, Bertrand R and Pommier Y: Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment. Leukemia 8: 792-797, 1994.
7. Solary E, Bertrand R, Kohn K and Pommier Y: Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81: 1359-1368, 1993.
8. Del Bino G, Li X, Traganos F and Darzynkiewicz Z: Altered susceptibility of HL-60 cells to apoptosis by antitumor drugs. Leukemia 8: 281-282, 1994.
9. Selvakumaran M, Reed JC, Liebermann D and Hoffman B: Progression of the myeloid differentiation program is dominant to transforming growth factor-ß1-induced apoptosis in Ml myeloid leukemia cells. Blood 84: 1036-1042, 1994.
10. Huang Y and Waxman S: Enhanced apoptosis in leukemia cells following treatment with combination fluoropyrimdines and differentiation inducers. Mol Cell Differ 2: 83-100, 1994.
11. 3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res 51: 3451-3455, 1991.
12. Yang GS, Minden MD and McCulloch EA: Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 7: 1012-1019, 1993.
13. Bhatia U, Traganos F and Darzynkiewicz Z: Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA-damaging drugs. Cell Growth Differ 6: 937-944, 1995.
14. Kraft AS, Williams F, Pettit GR and Lilly MB: Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 49: 1287-1293, 1989.
15. Stone RM, Sariban E, Pettit GR and Kufe DW: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72: 208-213, 1988.
16. Schucter LM, Esa AH, May WS, Laulis MK, Pettit GR and Hess AD: Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51: 682-687, 1991.
17. Hornung RL, Pearson JW, Beckwith M and Longo DL: Preclinical evaluation of bryostatin as an anticancer agent against several tumor cell lines: in vitro versus in vivo activity. Cancer Res 52: 101-107, 1992.
18. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Stern P, McDermott R, Potter M and Pettit GR: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418-424, 1993.
19. Grant S, Jarvis D, Swerdlow P, Turner A, Traylor R, Wallace H, Lin P-S, Pettit GR and Gewirtz DA: Potentiation of the activity of 1-ß-D-arabinofuranosylcytosine by the macrocyclic lactone PKC activator bryostatin 1 is associated with enhanced fragmentation of mature DNA. Cancer Res 52: 6270-6278, 1992.
20. Jarvis WD, Gewirtz DA, Povirk L, Turner A, Traylor R, Pettit GR and Grant S: Effect of bryostatin 1 and other activators of protein kinase C on 1-ß-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 839-852, 1994.
21. Grant S, Rao A, Freemerman AJ, Turner AJ, Kornstein MJ, Chelliah J and Jarvis WD: Divergent effects of calcium ionophore (A23187) on bryostatin 1-related differentiation and apoptosis in human promyelocytic leukemia cells (HL-60). Mol Cell Differ 3: 337-359, 1995.
22. Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L and Jarvis WD: Modulation of protein kinase C activity and calciumsensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Exp Cell Res 228: 65-75, 1996.
23. Jarvis DW, Kolesnick RW, Fomari FA, Traylor RS, Gewirtz DA and Grant S: Activation of the sphingomyelinase pathway initiates apoptosis in a variety of mammalian cell lines. Proc Natl Acad Sci USA 91: 73-77, 1994.
24. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of cell death in situ-via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
25. Freemerman AJ, Turner AJ, Birrer MJ, Szabo E, Valerie K and Grant S: Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacologic inhibitors of protein kinase C. Mol Pharmacol 49: 788-795, 1996.
26. Collins SJ: The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70: 1233-1244, 1987.
27. Jiang H, Lin J, Su Z-Z, Collart F, Huberman E and Fisher P: Induction of differentiation in human promyelocytic leukemic cells activates p21/WAF1/CIP1 expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
28. 3 in HL-60 cells. Cancer Res 56: 264-267, 1996.
29. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
30. Rao AS, Freemerman AJ, Jarvis WD, Chelliah J, Bear HD, Mikkelsen R and Grant S: Effects of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells. Leukemia 10: 1150-1158, 1996.
31. Shani A, Tichler T, Catane R, Gurwith M, Rozenszain LA, Schlesingcr M, Kalechman Y, Shalit F, Engelsman E, Farbstein H, Farbstein M, Albeck M and Sredni B: Immunological effects of AS101 in the treatment of cancer patients. Nat Immun Cell Growth Reg 9: 182-190, 1990.
32. Yin DX and Schimke RT: BCL-2 expression delays druginduced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922-4928, 1995.
33. Dewey WC, Miller HH and Leeper DP: Chromosomal aberrations and mortality of X-irradiated mammalian cells: emphasis on repair. Proc Natl Acad Sci USA 68: 667-671, 1971.
34. Lock RB and Stribinskiene L: Dual modes of cell death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006-4012, 1996.
35. Huberman E and Callaham MF: Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76: 1293-1297, 1979.
36. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA and Della Porta G: bcl-2 proto-oncogene expression in normal and neoplastic human myeloid leukemia cells. Blood 79: 1291-1298, 1992.
37. Griffin J, Munroe D, Major P and Kufe D: Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol 10: 774-781, 1982.
38. Murate T, Kagami Y, Hotta T, Yoshida T, Saito H and Yoshida S: Terminal differentiation of human erythroleukemia cell line K562 by aphidicolin. Exp Cell Res 191: 45-50, 1990.
39. Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J and Jarvis WD: Effect of 1-ß-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemic cells (U937) expressing a c-Jun dominantnegative mutant protein (TAM67). Cell Growth Differ 7: 603-613, 1996.
40. Hu Z-B, Minden MD and McCulloch EA: Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the ara-C sensitivity of leukemic stem cells. Leukemia 9: 1667-1673, 1995.
41. Samid D, Shack S and Sherman LT: Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
42. Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1997.
43. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G and Bhalla K: Overexpression of Bcl-xL inhibits ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 57: 3115-3130, 1997.
44. WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320-325, 1997.
45. Sherr CJ and Roberts JM: Inhibitors of mammalian Gl cyclindependent kinases. Genes Dev 9: 1149-1163, 1995.
46. Waldman T, Lengauer C, Kinzler KW and Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716, 1996.
47. K1PI on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-1210, 1997.
48. Kizaki H, Tadakuma T, Odaka C, Muramatsu J and Ishimura Y: Activation of a suicide process of thymocytes through DNA fragmentation by calcium ionophores and phorbol esters. J Immunol 143: 1790-1794, 1989.
49. Hedley DW and McCulloch EA: Generation of reactive oxygen intermediates after treatment with of blasts of acute mylegenous leukemia with 1-ß-D-arabinofuranosylcytosine: role of Bcl-2. Leukemia 10: 1143-1149, 1996.
50. Kubota M, Kataoka A, Okuda A, Bessho R, Lin YW, Usami I, Akiyama Y and Furosho K: Selection and partial characterization of calcium ionophore (A23187) resistant cells. Biochem Biophys Res Commun 213: 541-549, 1995.